Condition: Advanced Solid Tumor · Sponsor: Adcendo ApS
Adcendo ApS is conducting a phase 1 study of an investigational drug called ADCE-T02 (previously known as AMT-754), a tissue factor targeted antibody-drug conjugate which may be used in the future as a possible treatment for advanced solid tumors. The main purpose of the study is to determine the Maximum Tolerated Dose (MTD), the recommended dose and the safety and tolerability of ADCE-T02 when given as a single therapy over a range of different dose levels.
This description comes directly from the study's public registry record.
Margaret Mcnaull · +44 7818457619 · margaret.mcnaull@adcendo.com
Sarah Berardini · sarah.berardini@adcendo.com
Always discuss trial participation with your own doctor first.
| Highlands Oncology Group | Rogers, Arkansas, United States | Recruiting |
| Yale University Cancer Center | New Haven, Connecticut, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| START San Antonio | San Antonio, Texas, United States | Recruiting |
| Macquarie University Hospital | Macquarie Park, New South Wales, Australia | Recruiting |
| Scientia Clinical Research | Randwick, New South Wales, Australia | Recruiting |
| Southern Oncology Clinical Research Unit | Bedford Park, South Australia, Australia | Recruiting |
| Peninsula and South Eastern Haematology and Oncology Group (PSEHOG) | Frankston, Victoria, Australia | Recruiting |
| Cabrini Hospital | Malvern, Victoria, Australia | Recruiting |
| Peter MacCallum Cancer Centre | Melbourne, Victoria, Australia | Recruiting |
| Linear Clinical Research | Nedlands, Western Australia, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06597721